Application of a Concise Video to Improve Patient Understanding of Tumor Genomic Testing in Community and Academic Practice Settings

This study demonstrates that a concise, 3-4 minute educational video significantly and sustainably improves patient-specific knowledge regarding tumor genomic testing across diverse cancer types and both community and academic clinical settings.

The Gist

Imagine you are about to go on a very complex journey to fix a broken machine inside your body. The mechanic (your doctor) tells you they need to run a special diagnostic scan called Tumor Genomic Testing (TGT). This scan looks at the "code" of your cancer to see if there's a specific key that can unlock a targeted treatment.

However, in the past, doctors often handed you the scan order and said, "Go do this," without explaining why it matters, what the results might mean for your family, or who pays for it. It was like being handed a map to a foreign country without knowing the language or the currency.

This paper is about a study that tried to fix that confusion using a 3-to-4-minute animated video. Think of this video as a "pre-flight safety briefing" before you board the plane of cancer treatment.

Here is the breakdown of what they did and what they found, using some simple analogies:

1. The Problem: The "Information Gap"

The researchers noticed that while TGT is now standard care (like wearing a seatbelt), many patients didn't fully understand what it was.

• The Analogy: Imagine trying to assemble a piece of IKEA furniture, but the instructions are missing. You might get the job done, but you'll be stressed, confused, and might not trust the person selling you the furniture.
• The Reality: Patients were often unsure if the test would change their treatment, if it would cost a fortune, or if the results would accidentally reveal genetic secrets about their children.

2. The Solution: The "Video Briefing"

The team created a short, friendly, animated video (available in English and Spanish) that explained:

• What the test actually does.
• That it might help choose the right medicine, but not always (managing expectations).
• That results might sometimes reveal genetic risks for family members (incidental findings).
• That insurance usually covers it.

They tested this video in two different "neighborhoods":

• Academic Centers: Big university hospitals with lots of specialists.
• Community Centers: Local hospitals and clinics where most people get their care.

They also tested it on different types of cancer patients (Breast, Lung, and "Other").

3. The Experiment: The "Before, During, and After" Test

The researchers asked 203 patients to take a quiz at three different times:

• Time 1 (Before the video): "What do you know about this test right now?"
• Time 2 (Immediately after the video): "What did you just learn?"
• Time 3 (Months later, after getting results): "Do you still remember what you learned?"

They also checked if the video changed how much patients trusted their doctors or how much they knew about genetics in general (like whether you can see a gene with your naked eye—spoiler: you can't).

4. The Results: The "Lightbulb Moment"

The findings were very encouraging:

• The Video Worked: Right after watching the video, patients' knowledge about the specific topics covered jumped up significantly. It was like turning on a light in a dark room.
• The Memory Lasted: Even months later, when they got their actual test results, they still remembered the key points from the video. The knowledge didn't just fade away.
• It Worked Everywhere: It didn't matter if the patient was at a fancy university hospital or a local community clinic. The video helped everyone equally.
• It Worked for Everyone: It helped patients with different incomes and education levels.

What didn't change?
The video didn't magically make people know more about general science (like how DNA works in the abstract), nor did it change how much they trusted their doctors. This is actually good news! It proves the video was doing exactly what it was supposed to do: teaching specific facts, not trying to rewrite the patient's entire personality or general education.

5. The "Oops" Moment: The Follow-Up

There was one interesting side note. The video explained that sometimes the tumor test finds genetic clues about the patient's inherited health (like a hidden warning sign for family members).

• The Reality Check: Even though the video explained this clearly, when the researchers looked at the medical records, they found that doctors often forgot to refer patients to a genetic counselor when they found these clues.
• The Analogy: The video was like a fire alarm that successfully woke everyone up, but the fire department (the referral system) was sometimes slow to arrive. The video did its job; the system needs to catch up.

The Bottom Line

This study shows that a short, simple video is a powerful tool. It's like giving every patient a personalized user manual for their cancer treatment before they even start.

• For Patients: It reduces fear and confusion. You know what to expect, what it costs, and what the results mean for your family.
• For Doctors: It saves time. Instead of spending 20 minutes explaining the basics, they can say, "Watch this 4-minute video, and then let's discuss your specific results."
• For the System: It levels the playing field. Whether you live in a big city or a small town, you get the same clear, high-quality information.

The video is now free for anyone to use online, acting as a universal translator between complex cancer science and the everyday patient.

Technical Summary

1. Problem Statement

Tumor Genomic Testing (TGT) has become the standard of care for most patients with advanced or metastatic cancer, driving treatment decisions and identifying targeted therapies. However, despite established guidelines from organizations like ASCO and ACMG, pre-test patient education is frequently inconsistent, incomplete, or omitted due to clinical time constraints.

• Knowledge Gaps: Patients often lack understanding of TGT benefits, limitations, risks (including incidental germline findings), and insurance coverage.
• Impact on Care: Previous studies indicated that patients undergoing TGT without adequate education reported decreased confidence in their treatment plans, particularly when results did not lead to a change in therapy.
• Disparities: There is a need to determine if educational interventions are effective across diverse settings (academic vs. community oncology) and cancer types, given potential differences in patient demographics (education, income) and care delivery models.

2. Methodology

The study was a prospective interventional trial (ClinicalTrials.gov NCT05215769) conducted across academic (The Ohio State University) and community (Bon Secours Mercy Health) oncology sites.

Study Design & Cohorts:

• Participants: 203 patients with biopsy-confirmed cancer undergoing standard-of-care TGT.
• Cohorts:
  • Cohort 1: Metastatic Breast Cancer (MBC).
  • Cohort 2: Lung Cancer (LC).
  • Cohort 3: Other cancer types (Tumor-agnostic).
  • Cohort 4: Community-based patients (any cancer type).
• Intervention: A concise, 3–4 minute animated educational video available in English and Spanish. The video was modular, with specific 16-second clips added for MBC and LC cohorts to address cancer-specific treatment probabilities.
• Data Collection: Participants completed surveys at three timepoints:
  • T1: Pre-video (Baseline).
  • T2: Immediately post-video.
  • T3: After the return of TGT results (weeks/months later).

Outcome Measures:

1. Video Message-Specific Knowledge (VMSK): Primary endpoint. 10 true/false questions assessing understanding of specific video content (e.g., incidental findings, insurance coverage, impact on treatment).
2. Genomic Knowledge/Understanding (GKU): Secondary endpoint. 10 true/false questions on general genetics (serving as a control to ensure improvements were video-specific, not general learning).
3. Trust in Physician/Provider (TIPP): 11-item Likert scale measuring trust.
4. Knowledge Sufficiency/Insufficiency (KSI): Self-assessment of knowledge gaps.
5. Chart Review: Retrospective review of 176 OSU patients to assess adherence to ESMO guidelines for germline follow-up of incidental findings.

Statistical Analysis:

• Friedman test for repeated measures (T1 vs. T2 vs. T3).
• McNemar's test for changes in specific question accuracy.
• Spearman correlations and Kruskal-Wallis tests for demographic associations.

3. Key Contributions

• Scalable Educational Tool: Development and validation of a publicly available, mobile-friendly, culturally diverse video resource that standardizes TGT education across different cancer types and care settings.
• Durability of Effect: Demonstration that knowledge retention persists not just immediately after viewing, but also after the return of clinical results (T3).
• Community vs. Academic Parity: Evidence that the intervention is equally effective in community oncology settings, which often face greater resource constraints than academic centers.
• Identification of Systemic Gaps: The study highlighted a critical disconnect between TGT results and germline follow-up, revealing that even with education, systemic barriers prevent the referral of patients with incidental germline findings.

4. Key Results

Demographics:

• The cohort was 65% female, 88% White, with a median age of 63.
• Baseline VMSK and GKU scores were significantly associated with higher income and education levels.

Primary Outcome (VMSK):

• Significant Improvement: VMSK scores increased significantly from T1 to T2 and were sustained at T3 ($P_{overall} < 0.0001$).
  • Mean VMSK: T1 (87.1%) $\rightarrow$ T2 (94.2%) $\rightarrow$ T3 (91.0%).
• Consistency: Improvement was observed across all four cohorts (Breast, Lung, Other, Community).
• Specific Knowledge Gains: Four specific questions showed significant and retained improvement (T1 to T3):
  1. Necessity of TGT for continuing treatment.
  2. Potential for results to raise further questions requiring more testing.
  3. Likelihood of referral to a genetics specialist.
  4. Insurance coverage of testing costs.

Secondary Outcomes:

• GKU & TIPP: No significant changes were observed in general genomic knowledge (GKU) or trust in providers (TIPP) over time, confirming that the VMSK improvement was specific to the video content and not a result of general maturation or increased trust.
• Patient Perception: >90% of participants rated the video as "helpful," and most felt the information amount was "just right." The perceived gap between "knowledge possessed" and "knowledge needed" narrowed significantly after the video.

Germline Follow-up (Chart Review):

• Of 176 reviewed patients, 18 (10%) met ESMO guidelines for germline follow-up.
• Critical Finding: Only 3 of the 10 patients who had not previously undergone germline testing were referred for genetic counseling or follow-up testing.
• Seven patients with pathogenic variants in high-risk genes (e.g., BRCA2, ATM, PTEN) were not referred, indicating a persistent systemic failure in translating TGT results into germline care despite the educational intervention.

5. Significance

• Clinical Practice: This study provides evidence that a brief, standardized video intervention can effectively bridge the knowledge gap regarding TGT for diverse patient populations, addressing a major barrier to informed consent and shared decision-making.
• Equity: The success in community settings suggests this tool can help level the playing field for patients treated outside of major academic centers, where access to specialized genetic counselors may be limited.
• Policy & Guidelines: The findings support ASCO and ACMG recommendations for innovative education delivery (video/AI) to alleviate provider burden.
• Unmet Need: While the video successfully educated patients, the study underscores that education alone does not solve systemic workflow issues. The low rate of germline follow-up referrals indicates that clinical pathways for managing incidental findings require further optimization to ensure patients receive necessary risk-reducing care.

Conclusion:
The concise video intervention is a highly effective, durable, and scalable solution for improving patient understanding of tumor genomic testing across various cancer types and care settings. However, the study also highlights that patient education must be paired with robust clinical workflows to ensure incidental germline findings are acted upon. The resource is publicly available at http://www.tumor-testing.com.